Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Celgene’s fedratinib gets FDA priority review for myelofibrosis

pharmaceutical-technologyMarch 08, 2019

Tag: FDA , fedratinib , Celgene

PharmaSources Customer Service